Brain scans may reveal how MS drug affects mental fatigue

NCT ID NCT04565431

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study explores whether the medication Tysabri can reduce cognitive fatigue—the tiredness that comes after intense mental effort—in people with relapsing-remitting multiple sclerosis (RRMS). Researchers will compare brain activity, measured with functional MRI, between RRMS patients starting Tysabri and healthy volunteers matched by age, gender, and education. The goal is to see if changes in brain activation correlate with fatigue levels, potentially identifying a biomarker for cognitive fatigue in MS.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tysabri (natalizumab), a drug used to treat multiple sclerosis
What this could lead to
If successful, this could point toward a way to measure and treat cognitive fatigue in multiple sclerosis, improving daily life for patients.
What could go wrong
This is a very small early-stage study (7 participants), so results may not apply broadly. It focuses on brain imaging markers rather than direct patient outcomes, and the drug may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kessler Foundation

    West Orange, New Jersey, 07052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.